Viatris IncVTRS
▼ NegativeCapitalrelevance
Q2 results beat estimates but stock fell on negative market reaction despite raised guidance.
Impact on stocks 1
Biotech & Genomic Medicine
Viatris IncViatris reported second-quarter results that beat Wall Street expectations but still drew a negative market reaction. Revenue came in at $3.76 billion versus analyst estimates of $3.68 billion, a 4.9% year-on-year increase, while adjusted EPS of $0.69 beat estimates of $0.60 by 15%. Management raised full-year revenue guidance to $14.75 billion at the midpoint and adjusted EPS guidance to $2.52, a 5% increase. Analysts focused on China's growth durability, e-commerce contribution, selatogrel's trial design, fast-acting meloxicam's commercial potential, manufacturing disruptions, and cenerimod's clinical data. CEO Scott Smith highlighted strong commercial execution in Greater China and higher-margin generics in North America, while supply chain disruptions and lower-margin products in emerging markets weighed on results.
Viatris IncQ2 results beat estimates but stock fell on negative market reaction despite raised guidance.